Shares of Azitra (AZTR) experienced a significant rally following the announcement of a securities purchase agreement with healthcare-focused institutional investors. The agreement is projected to generate gross proceeds of up to $31.4 million, aimed at strengthening the company's financial position. As part of the deal, Azitra will issue Series A convertible preferred stock along with Series B and C warrants. The warrants are set to be exercisable at a price of $0.123 per share, providing a structured path for further capital injection. This substantial capital raise is expected to fund ongoing operations and support the company's strategic initiatives in the biotech sector. While the liquidity boost is viewed as a positive development, the warrant pricing reflects potential future dilution for existing shareholders.
Sign up free to access this content
Create Free Account